AWM
ENTA icon

Abound Wealth Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Abound Wealth Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7
Closed -$150 – 1182
2023
Q2 		$150 Buy
+7
New +$206 ﹤0.01% 1167

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abound Wealth Management's ENTA Position: Q3 2023 in Review

Abound Wealth Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 7 shares — an estimated $150 sold.

Abound Wealth Management first reported a position in ENTA in Q2 2023 and held it in 1 quarter. The position peaked at $150 in Q2 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • Abound Wealth Management reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Abound Wealth Management sold 7 Enanta Pharmaceuticals shares in Q3 2023, an estimated $150.
  • Abound Wealth Management first reported a position in Enanta Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Abound Wealth Management's Enanta Pharmaceuticals position peaked at $150 in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on Abound Wealth Management's 13F filing for Q3 2023, filed 8 Aug 2024.